Journal: Advances in Radiation Oncology

Article Title: Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model

doi: 10.1016/j.adro.2026.102051

Figure Lengend Snippet: Biochemical structures of Linebacker-1 (LB1) and myricetin and antineoplastic effect of LB1 with/without radiation in human colon and lung cell lines. (A) Myricetin (left) and LB1 (right) showing with a red circle for the OH ion’s replacement by a cloride ion (Cl). (B) Schematic diagram of the treatment design using LB1 for in vitro study. (C) and (D) MTT growth assay using OD value 570 nm, showing the antitumor effect of LB1 in titrated doses for both human colon (HT29) and lung (A549) cancer cell lines, respectively. (E) Bar graph representing the colony count numbers from the clonogenic survival assay after LB1 treatment. (F) Schematic diagram showing the treatment design for in vitro LB1 and radiation treatment. Doses of 0, 25, 50, and 75 µM LB1, along with single radiation fractions of 0, 2, 4, and 6 Gy, were used in the clonogenic survival study. (G) For the clonogenic survival assay, colony counts are shown for A549 cells treated with 0, 2, 4, and 6 Gy of radiation, with or without LB1, at 0, 25, 50, and 75 µM. (H) colony count for A549 and Lewis lung carcinoma (LLC1) cell line , respectively. Graphs are generated from the average of at least 3 study repeats. The SD of the multiple independent repeats is shown, while statistical significance is shown by *** P < .001. Abbreviation : OD = optical density; OH = hydroxide ion; MTT = methyl dimethylthiazol diphenyltetrazolium bromide; RT = radiation therapy.

Article Snippet: A549 cells were cultured in RPMI cell culture media (Gibco), the HT29 cell line was cultured in McCoy’s 5A medium (ATCC), and the LLC1 cell was cultured in Dulbecco’s Modified Eagle Media (Gibco).

Techniques: In Vitro, Growth Assay, Clonogenic Cell Survival Assay, Generated

Journal: iScience

Article Title: Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC

doi: 10.1016/j.isci.2026.115883

Figure Lengend Snippet: oHSV-1 exhibits the characteristics of a standard one-step growth curve and can efficiently replicate and express exogenous genes (A) The results of virus titer determination of HSV-1/WT, RG2001m, RG2002m, RG2005m, RG2011m, and RG2012m in Vero cells 48 h after infection. (B) Vero cells were infected with oHSV-1 at a multiplicity of infection (MOI) = 1, and the virus titers were determined at 0, 8, 16, 24, 32, 40, and 48 h, respectively, and a growth curve was drawn. (C) The results of virus titer determination of oHSV-1 in colon cancer cells (CT26, HCT116, and HT29) 48 h after infection. (D–F) The growth curves of oHSV-1 in colon cancer cells (CT26, HCT116, and HT29). (G) At MOI = 10, IL-15 expression levels in cell supernatants of HSV-1/WT, RG2001m, RG2005m, and RG2012m at 24, 48, and 72 h post-infection (mouse IL-15 ELISA Kit, elabscience). (H) At MOI = 10, IL-12 expression levels in cell supernatants of HSV-1/WT, RG2002m, RG2005m, and RG2012m at 24, 48, and 72 h post-infection (mouse IL-12 ELISA Kit, elabscience). (I) At MOI = 10, chemokine CCL5 expression levels in cell supernatants of HSV-1/WT, RG2011m, and RG2012m at 24, 48, and 72 h post-infection (mouse CCL5 ELISA Kit, elabscience). (Data are presented as mean ± SD. Comparisons between datasets were performed using one-way ANOVA and Student’s t test, with p values calculated [ n = 3]) ( p > 0.05, ns; p < 0.05, ∗; p < 0.01, ∗ ∗; p < 0.001, ∗ ∗ ∗).

Article Snippet: CT26, HTC116, and HT29 cells were purchased from Wuhan Procell Life Science & Technology Co., Ltd., China (Cat. No. CL-0071; Cat. No. CL-0096; Cat. No. CL-0118).

Techniques: Virus, Infection, Expressing, Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC

doi: 10.1016/j.isci.2026.115883

Figure Lengend Snippet: Killing effect of recombinant oHSV-1 on colon cancer cells (A–C) CT26 (A), HCT116 (B), and HT29 (C) colon cancer cells were infected with recombinant oncolytic virus at multiplicity of infection (MOI) of 0.5, 1, and 5, respectively. The cell killing rate was detected by cell counting kit-8 (CCK8) assay 48 h after infection. The results showed that the killing effect of the virus on the three colon cancer cells was enhanced in an MOI - dependent manner. (D–F) CT26 (D), HCT116 (E), and HT29 (F) cells were infected with recombinant oncolytic virus at MOI = 1. The killing rate was measured by CCK8 assay at 24, 48, and 72 h after infection, suggesting that the killing effect of the virus on colon cancer cells was significantly enhanced with the prolongation of action time. (The values are presented as mean ± SD. The datasets were compared via one-way ANOVA. n = 3) ( p > 0.05, ns; p < 0.05, ∗; p < 0.01, ∗ ∗; p < 0.001, ∗ ∗ ∗.).

Article Snippet: CT26, HTC116, and HT29 cells were purchased from Wuhan Procell Life Science & Technology Co., Ltd., China (Cat. No. CL-0071; Cat. No. CL-0096; Cat. No. CL-0118).

Techniques: Recombinant, Infection, Virus, Cell Counting, CCK-8 Assay

Journal: iScience

Article Title: Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC

doi: 10.1016/j.isci.2026.115883

Figure Lengend Snippet: oHSV-1 exhibits the characteristics of a standard one-step growth curve and can efficiently replicate and express exogenous genes (A) The results of virus titer determination of HSV-1/WT, RG2001m, RG2002m, RG2005m, RG2011m, and RG2012m in Vero cells 48 h after infection. (B) Vero cells were infected with oHSV-1 at a multiplicity of infection (MOI) = 1, and the virus titers were determined at 0, 8, 16, 24, 32, 40, and 48 h, respectively, and a growth curve was drawn. (C) The results of virus titer determination of oHSV-1 in colon cancer cells (CT26, HCT116, and HT29) 48 h after infection. (D–F) The growth curves of oHSV-1 in colon cancer cells (CT26, HCT116, and HT29). (G) At MOI = 10, IL-15 expression levels in cell supernatants of HSV-1/WT, RG2001m, RG2005m, and RG2012m at 24, 48, and 72 h post-infection (mouse IL-15 ELISA Kit, elabscience). (H) At MOI = 10, IL-12 expression levels in cell supernatants of HSV-1/WT, RG2002m, RG2005m, and RG2012m at 24, 48, and 72 h post-infection (mouse IL-12 ELISA Kit, elabscience). (I) At MOI = 10, chemokine CCL5 expression levels in cell supernatants of HSV-1/WT, RG2011m, and RG2012m at 24, 48, and 72 h post-infection (mouse CCL5 ELISA Kit, elabscience). (Data are presented as mean ± SD. Comparisons between datasets were performed using one-way ANOVA and Student’s t test, with p values calculated [ n = 3]) ( p > 0.05, ns; p < 0.05, ∗; p < 0.01, ∗ ∗; p < 0.001, ∗ ∗ ∗).

Article Snippet: HT29 , Wuhan Procell Life Science & Technology Co., Ltd., China , Cat. No. CL-0118; RRID: CVCL_0320.

Techniques: Virus, Infection, Expressing, Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC

doi: 10.1016/j.isci.2026.115883

Figure Lengend Snippet: Killing effect of recombinant oHSV-1 on colon cancer cells (A–C) CT26 (A), HCT116 (B), and HT29 (C) colon cancer cells were infected with recombinant oncolytic virus at multiplicity of infection (MOI) of 0.5, 1, and 5, respectively. The cell killing rate was detected by cell counting kit-8 (CCK8) assay 48 h after infection. The results showed that the killing effect of the virus on the three colon cancer cells was enhanced in an MOI - dependent manner. (D–F) CT26 (D), HCT116 (E), and HT29 (F) cells were infected with recombinant oncolytic virus at MOI = 1. The killing rate was measured by CCK8 assay at 24, 48, and 72 h after infection, suggesting that the killing effect of the virus on colon cancer cells was significantly enhanced with the prolongation of action time. (The values are presented as mean ± SD. The datasets were compared via one-way ANOVA. n = 3) ( p > 0.05, ns; p < 0.05, ∗; p < 0.01, ∗ ∗; p < 0.001, ∗ ∗ ∗.).

Article Snippet: HT29 , Wuhan Procell Life Science & Technology Co., Ltd., China , Cat. No. CL-0118; RRID: CVCL_0320.

Techniques: Recombinant, Infection, Virus, Cell Counting, CCK-8 Assay